Pasithea Therapeutics Cor... (KTTA)
NASDAQ: KTTA
· Real-Time Price · USD
0.93
-0.01 (-1.17%)
At close: May 23, 2025, 3:59 PM
0.94
0.95%
After-hours: May 23, 2025, 05:53 PM EDT
-1.17% (1D)
| Bid | 0.9 |
| Market Cap | 6.92M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.57B |
| EPS (ttm) | -10.6 |
| PE Ratio (ttm) | -0.09 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.94 |
| Volume | 212,502 |
| Avg. Volume (20D) | 6,114,953 |
| Open | 0.91 |
| Previous Close | 0.94 |
| Day's Range | 0.91 - 0.94 |
| 52-Week Range | 0.80 - 7.50 |
| Beta | 0.54 |
About KTTA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol KTTA
Website n/a
1 week ago
+11.09%
Pasithea Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
1 week ago
+11.07%
Pasithea Therapeutics shares are trading higher after the company announced initiation of its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PAS-004, in adult participants with neurofibromatosis type 1 with symptomatic and inoperable, incompletely resected, or recurrent plexiform neurofibromas.
